It was a positive week for the European Medicines Agency’s human medicines committee (CHMP), which recommended the approval ...
Ipsen’s new sponsored TikTok features the popular “Of course” trend and two social influencers, but with a rare disease twist ...
Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health ...
We’re in a frothy time,” acknowledges Alexandra Snyder, the head of R&D at Generate:Biomedicines. Generate is one of the ...
Cigna’s health services arm Evernorth said on Thursday that it plans to offer a cheaper copycat of AbbVie’s blockbuster drug ...
UCB is shaking up its leadership team “to better align with its commitment to growth and innovation, and to better address ...
The FDA on Friday approved a label update on Biktarvy, Gilead’s blockbuster HIV drug, to include more data on the drug’s safety and efficacy for pregnant people with HIV. The additional data reflected ...
AbbVie's effort to protect Humira's market share is getting expensive. On Friday, the company announced a 40% decline in the megablockbuster drug's US sales for the first quarter. While it managed to ...
RevOpsis Therapeutics secures $16.5M seed round: The San Carlos, CA-based biotech will use the funds to complete IND-enabling studies for its lead candidate, RO-104, for neovascular age-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results